Adjunctive and therapeutic progestins in XXXX .

@entity1204 @entity1 @entity0 @entity7839 @entity5 @entity7828 @entity1871 @entity134 @entity3
With the arrival of @entity1871 therapy for advanced, metastatic and recurrent @entity1204 a quarter of a century ago, came the discovery that approximately one-third of all these @entity5 would show a clinical response. Probably no more than half of this group will survive more than 5 years. Identification of the type of @entity1 who is most likely to respond has proven difficult. Both clinical and histopathological characteristics act only as an unreliable guide. The site of @entity3 and the time for a recurrence to appear are the most constant of these factors. It is hoped that the @entity134 receptor content of the @entity5 will prove to be as valuable as it has been in the case of @entity0 . At the moment this is under investigation with numerous ongoing studies. Type, dosage and mode of administration of @entity1871 do not appear to be critical factors in @entity5 response, nor does the type of synthetic agent used. However, @entity7839 has been the subject of numerous symposia and is the best researched. It also offers the opportunity of being administered orally and in large doses. All agents are virtually free of toxic effects and cessation on this basis is unusual. For @entity1 with @entity5 that either do not respond to @entity1871 , or else have a temporary response, other agents--antiestrogens and cytotoxic--may well prove to be of value either simultaneously or sequentially. These possibilities are under current investigation. The definitive therapy of primary 'nonadvanced' disease is not established and is at this point unproven in any significant published randomized study. Orthodox proven methods of treatment, i.e. surgery and irradiation, must form the initial component in every @entity1 's therapy, whatever the stage of the disease. It is hoped that prospective studies will elucidate the place of @entity7828 in an adjunctive primary setting. However, it must be emphasized that such studies must concentrate on 'high-risk' @entity1 . The probability of proof in any group of 'good prognosis' @entity1 --whatever the numbers entered--appears to be very low.
